Search

Your search keyword '"Thambisetty, Madhav"' showing total 677 results
Start Over Author "Thambisetty, Madhav"
677 results on '"Thambisetty, Madhav"'

101. Additional file 21: of Deep proteomic network analysis of Alzheimerâ s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Abstract

Figure S14. Differential Abundance of Alternative Exon-Exon Junction Peptides by TMT Network Module. For case group comparisons AD vs. AsymAD (top), AD vs. control (middle), and AsymAD vs. control (bottom), the fraction of alternative exon-exon junction (alt-EEjxn) peptides within each network module that were significantly different between the two case groups was plotted by bar graph, with each bar color coded according to the average log2 difference of the alt-EEjxn peptides in each direction (increased or decreased). The arrows in the AD vs. AsymAD comparison highlight modules that showed an increase in the fraction of alt-EEjxns or an increase in the magnitude of differential abundance, or both, compared to AD vs. control. (PDF 718Â kb)

Published
2018
Full Text
View/download PDF

102. Additional file 7: of Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Abstract

Table S7. AD Risk Factor Protein Alternative Exon-Exon Junction Peptides Significantly Altered by Case Status. Of the five AD risk factor proteins that had quantifiable alt-EEjxn peptides in the BLSA-TMT analysis, three had alt-EEjxn peptides that were significantly, or nearly significantly, different in abundance by case status. For PTK2B 20038, module eigenprotein correlation was not performed due to the number of missing values for quantitation (≥25). A complete description of each alt-EEjxn peptide is provided in Supplementary Data. ME bicor, module eigenprotein bicorrelation; kME, correlation value to the module eigenprotein; AD, Alzheimer’s disease; AsymAD, asymptomatic Alzheimer’s disease. (DOCX 29 kb)

Published
2018
Full Text
View/download PDF

103. Additional file 14: of Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Abstract

Figure S7. Differential Protein Abundance between AD and AsymAD. Proteins that were significantly increased (160) or decreased (190) in AD compared to AsymAD, color-coded by TMT network module membership, are shown. The horizontal dotted line represents p = 0.05. Interactive plots for AD vs. AsymAD, AD vs. control, and AsymAD vs. control differential protein abundance are provided in Supplementary Data. (PDF 10400 kb)

Published
2018
Full Text
View/download PDF

104. Additional file 12: of Deep proteomic network analysis of Alzheimerâ s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Subjects
mental disorders
Abstract

Figure S5. TMT Protein Network Modules Enriched for AD Risk Factors. Graphical representation of the correlation relationships among TMT network module proteins for the four modules identified to contain enrichment of AD risk factors from GWAS, along with the relationship of each module to case status, neuritic amyloid plaque load (CERAD score), and tau tangle burden (Braak stage). Proteins identified by GWAS as AD risk factors are highlighted in red. Only the top 100 proteins by kME value are shown for the M4 yellow (257 total proteins) and M7 black (162 total proteins) modules. (PDF 462Â kb)

Published
2018
Full Text
View/download PDF

105. Additional file 9: of Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Subjects
human activities
Abstract

Figure S2. Protein Quantitation in TMT-LysC and LFQ-trypsin Analyses. The relationship between the number of quantifiable proteins at a given threshold of missing values in the 47 brain samples from the BLSA cohort for TMT-LysC and LFQ-trypsin analyses is shown. The point at 23 samples and 6533 proteins represents the threshold used for the TMT-LysC analysis pipeline in this study. This point falls slightly below the TMT curve because 11 MCI samples were included in the TMT analysis workflow, for a total of 58 samples, but were later dropped from the analysis (see Methods). The increased number of samples when including the 11 MCI cases slightly reduced the number of quantifiable proteins at the ~ 50% missing value threshold. (PDF 79 kb)

Published
2018
Full Text
View/download PDF

106. Additional file 8: of Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Abstract

Figure S1. SDS-PAGE of Brain Homogenates. Dorsolateral prefrontal cortex (DLPFC) brain tissue homogenates from cases shown in Table S1 were analyzed by SDS-PAGE to assess sample integrity prior to TMT labeling and mass spectrometry analysis. Gels were stained with Coomassie Blue to visualize protein. AD, Alzheimer’s disease; AS, asymptomatic Alzheimer’s disease; CT, control; MCI, mild cognitive impairment. (PDF 22000 kb)

Published
2018
Full Text
View/download PDF

107. Additional file 3: of Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Subjects
nervous system, mental disorders, behavioral disciplines and activities, human activities
Abstract

Table S3. TMT Experimental Design. MCI cases (n = 11) were removed after batch correction. The final cohort used for quantification was n = 47 DLPFC non-MCI samples. TMT, tandem mass tag; GIS, global internal standard; BLSA, Baltimore Longitudinal Study of Aging; AD, Alzheimer’s disease; AsymAD, asymptomatic Alzheimer’s disease; MCI, mild cognitive impairment; DLPFC, dorsolateral prefrontal cortex. (PDF 888 kb)

Published
2018
Full Text
View/download PDF

108. Additional file 4: of Deep proteomic network analysis of Alzheimerâ s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Abstract

Table S4. List of Biological Terms for GO Network in Figure S8. GO, gene ontology; UP, UniProt; KEGG, Kyoto Encyclopedia of Genes and Genomes; SMART, Simple Modular Architecture Research Tool; FDR, false discovery rate. (DOCX 35Â kb)

Published
2018
Full Text
View/download PDF

109. Additional file 2: of Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Subjects
mental disorders
Abstract

Table S2. Case Characteristics. Values shown are means ± SD. AD, Alzheimer’s disease; AsymAD, asymptomatic Alzheimer’s disease; MCI, mild cognitive impairment; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease amyloid-β plaque load score; Braak, Braak stage for tau tangle burden; PMI, post-mortem interval; ApoE, apolipoprotein E isoform genotype. (DOCX 30 kb)

Published
2018
Full Text
View/download PDF

110. Additional file 6: of Deep proteomic network analysis of Alzheimerâ s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Abstract

Table S6. Number of Alternative Exon-Exon Junctions in AD Risk Factor Proteins. From the twenty proteins identified as risk factors for AD by GWAS at genome-wide significance [12], five had alt-EEjxn peptides that were observed and quantifiable in the BLSA-TMT analysis (observed). The number of observed and quantifiable alt-EEjxn peptides for each of these five proteins was a subset of the total number of alt-EEjxn peptides predicted to exist after LysC digestion (peptide database). This number was a further subset of the total number of alt-EEjxns observed for each of the five proteins from RNAseq data (transcript level). For details on generation of the peptide database and transcript level numbers, see Methods. (DOCX 28Â kb)

Published
2018
Full Text
View/download PDF

111. Additional file 5: of Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease

Author

Johnson, Erik, Dammer, Eric, Duong, Duc, Luming Yin, Thambisetty, Madhav, Troncoso, Juan, Lah, James, Levey, Allan, and Seyfried, Nicholas

Abstract

Table S5. Number of Alternative Exon-Exon Junction Peptides Identified by TMT-LysC and LFQ-trypsin Approaches. The number of alt-EEjxn peptides identified by matching to the listed databases (Swiss-Prot, Trembl, or RNAseq) is shown, along with the number of quantifiable alt-EEjxn peptides. A peptide was considered quantifiable in this analysis if it had a minimum of 2 measurements in at least 2 different case groups. RNAseq data from control and AD patient brains (n = 6) were used to generate the RNAseq alt-EEjxn peptide database, as described in Methods. (DOCX 28 kb)

Published
2018
Full Text
View/download PDF

113. A Consensus Proteomic Analysis of Alzheimer’s Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation

Author

Johnson, Erik C.B., primary, Dammer, Eric B., additional, Duong, Duc M., additional, Ping, Lingyan, additional, Zhou, Maotian, additional, Yin, Luming, additional, Higginbotham, Lenora A., additional, Guajardo, Andrew, additional, White, Bartholomew, additional, Troncoso, Juan C., additional, Thambisetty, Madhav, additional, Montine, Thomas J., additional, Lee, Edward B., additional, Trojanowski, John Q., additional, Beach, Thomas G., additional, Reiman, Eric M., additional, Haroutunian, Vahram, additional, Wang, Minghui, additional, Schadt, Eric, additional, Zhang, Bin, additional, Dickson, Dennis W., additional, Ertekin-Taner, Nilufer, additional, Golde, Todd E., additional, Petyuk, Vladislav A., additional, De Jager, Philip L., additional, Bennett, David A., additional, Wingo, Thomas S., additional, Rangaraju, Srikant, additional, Hajjar, Ihab, additional, Shulman, Joshua M., additional, Lah, James J., additional, Levey, Allan I., additional, and Seyfried, Nicholas T., additional

Published
2019
Full Text
View/download PDF

114. Cerebral atherosclerosis contributes to Alzheimer’s dementia independently of its hallmark amyloid and tau pathologies

Author

Wingo, Aliza P., primary, Fan, Wen, additional, Duong, Duc M., additional, Gerasimov, Ekaterina S., additional, Dammer, Eric B., additional, White, Bartholomew, additional, Thambisetty, Madhav, additional, Troncoso, Juan C., additional, Schneider, Julie A., additional, Lah, James J., additional, Bennett, David A., additional, Seyfried, Nicholas T., additional, Levey, Allan I., additional, and Wingo, Thomas S., additional

Published
2019
Full Text
View/download PDF

116. O4-10-04: LARGE-SCALE PROTEOMIC ANALYSIS OF HUMAN PREFRONTAL CORTEX IDENTIFIES PROTEINS ASSOCIATED WITH COGNITIVE TRAJECTORY IN ADVANCED AGE

Author

Wingo, Aliza P., primary, Dammer, Eric B., additional, Breen, Michael S., additional, Logsdon, Benjamin A., additional, Duong, Duc, additional, Troncoso, Juan C., additional, Thambisetty, Madhav, additional, Beach, Thomas G., additional, Serrano, Geidy E., additional, Reiman, Eric M., additional, Caselli, Richard J., additional, Lah, James J., additional, Seyfried, Nicholas T., additional, Levey, Allan I., additional, and Wingo, Thomas S., additional

Published
2019
Full Text
View/download PDF

118. O4-06-04: PRECISION MEDICINE INTERVENTION IN PATIENTS AT RISK FOR ALZHEIMER'S DEMENTIA

Author

Isaacson, Richard S., primary, Hristov, Hollie, additional, Saif, Nabeel, additional, Hackett, Katherine, additional, Hendrix, Suzanne B., additional, Melendez, Juan, additional, Safdieh, Joseph, additional, Fink, Matthew, additional, Lee, Paige, additional, Thambisetty, Madhav, additional, Berkowitz, Cara, additional, Rahman, Aneela, additional, Bellara, Sonia, additional, Meléndez-Cabrero, Josefina, additional, Caesar, Emily E., additional, Sadek, George, additional, Cohen, Randy, additional, Dickson, Samuel P., additional, Lu, Pei-Lin, additional, Hwang, Mu Ji, additional, Scheyer, Olivia, additional, Schelke, Matthew W., additional, Niotis, Kellyann, additional, Greer, Christine E., additional, Attia, Peter, additional, Mosconi, Lisa, additional, and Krikorian, Robert, additional

Published
2019
Full Text
View/download PDF

120. Large-scale proteomic analysis of human prefrontal cortex identifies proteins associated with cognitive trajectory in advanced age

Author

Wingo, Aliza P., primary, Dammer, Eric B., additional, Breen, Michael S., additional, Logsdon, Benjamin A., additional, Duong, Duc M., additional, Troncosco, Juan C., additional, Thambisetty, Madhav, additional, Beach, Thomas G., additional, Serrano, Geidy E., additional, Reiman, Eric M., additional, Caselli, Richard J., additional, Lah, James J., additional, Seyfried, Nicholas T., additional, Levey, Allan I., additional, and Wingo, Thomas S., additional

Published
2019
Full Text
View/download PDF

121. Neurotransmitter imbalance in the brain and Alzheimer’s pathology

Author

Pletnikova Olga, Amera A. Ebshiana, Troncoso John, Stuart G. Snowden, Legido-Quigley Cristina, Abdul Hye, Thambisetty Madhav, An Yang, and O'Brien Richard

Subjects
business.industry, Memantine, Physiology, Neuropathology, Human brain, medicine.anatomical_structure, Inferior temporal gyrus, Galantamine, Medicine, Middle frontal gyrus, Neurotransmitter metabolism, business, Donepezil, medicine.drug
Abstract

INTRODUCTIONThree of the four treatments for Alzheimer’s disease are cholinesterase inhibitors targeting the pathological reduction of acetylcholine levels. Here we aimed to determine the role of other neurotransmitter pathways in AD pathology.METHODSTissue samples were obtained from three groups, controls, AD and ‘asymptomatic AD’ i.e. cognitively normal individuals that had significant AD neuropathology. Three brain areas were studied, the middle frontal gyrus (MFG) the inferior temporal gyrus (ITG) and the cerebellum.RESULTS11 of 15 measured metabolites were shown to be associated with disease. Decreases in dopamine were seen in the ASYMAD group in the MFG when compared to control and AD patients (FC=0.78, p=4.1×10-3). In AD patients changes were mainly seen in the ITG’s inhibitory GABAergic system.DISCUSSIONThese results indicate that dopamine could be depleted in brains with Alzheimer’s pathology but intact cognition, while and imbalance of several neurotransmitters is evident in the brain of AD patients.

Published
2017
Full Text
View/download PDF

122. Neuropathologic, genetic, and longitudinal cognitive profiles in primary age‐related tauopathy (PART) and Alzheimer's disease

Author

Bell, W. Robert, primary, An, Yang, additional, Kageyama, Yusuke, additional, English, Collin, additional, Rudow, Gay L., additional, Pletnikova, Olga, additional, Thambisetty, Madhav, additional, O'Brien, Richard, additional, Moghekar, Abhay R., additional, Albert, Marilyn S., additional, Rabins, Peter V., additional, Resnick, Susan M., additional, and Troncoso, Juan C., additional

Published
2018
Full Text
View/download PDF

123. P1‐235: SEX‐SPECIFIC ASSOCIATIONS OF SERUM BILE ACIDS WITH BRAIN ATROPHY DURING AGING: DIFFERENTIAL EFFECTS OF CONJUGATION AND GUT MICROBIAL METABOLISM

Author

Varma, Vijay R., primary, Chuang, Yi-Fang, additional, An, Yang, additional, Huang, Chiung-Wei, additional, Oommenn, Anup, additional, Sonntag, Denise, additional, Armstrong, Nicole, additional, Davatzikos, Christos, additional, Legido-Quigley, Cristina, additional, Resnick, Susan M., additional, and Thambisetty, Madhav, additional

Published
2018
Full Text
View/download PDF

126. Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects

Author

Wong, Dean F., primary, Comley, Robert A., additional, Kuwabara, Hiroto, additional, Rosenberg, Paul B., additional, Resnick, Susan M., additional, Ostrowitzki, Susanne, additional, Vozzi, Cristina, additional, Boess, Frank, additional, Oh, Esther, additional, Lyketsos, Constantine G., additional, Honer, Michael, additional, Gobbi, Luca, additional, Klein, Gregory, additional, George, Noble, additional, Gapasin, Lorena, additional, Kitzmiller, Kelly, additional, Roberts, Josh, additional, Sevigny, Jeff, additional, Nandi, Ayon, additional, Brasic, James, additional, Mishra, Chakradhar, additional, Thambisetty, Madhav, additional, Moghekar, Abhay, additional, Mathur, Anil, additional, Albert, Marilyn, additional, Dannals, Robert F., additional, and Borroni, Edilio, additional

Published
2018
Full Text
View/download PDF

127. First in-human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948

Author

Wong, Dean F., primary, Comley, Robert A., additional, Kuwabara, Hiroto, additional, Rosenberg, Paul B., additional, Resnick, Susan M., additional, Ostrowitzki, Susanne, additional, Vozzi, Cristina, additional, Boess, Frank, additional, Oh, Esther, additional, Lyketsos, Constantine G., additional, Honer, Michael, additional, Gobbi, Luca, additional, Klein, Gregory, additional, George, Noble, additional, Gapasin, Lorena, additional, Kitzmiller, Kelly, additional, Roberts, Josh, additional, Sevigny, Jeff, additional, Nandi, Ayon, additional, Brasic, James, additional, Mishra, Chakradhar, additional, Thambisetty, Madhav, additional, Mogekar, Abhay, additional, Mathur, Anil, additional, Albert, Marilyn, additional, and Dannals, Robert F., additional

Published
2018
Full Text
View/download PDF

130. Utility of the Malayalam translation of the 7- minute screen for Alzheimer's disease risk in an Indian community

Author

De Jager, Celeste, Thambisetty, Madhav, Praveen, K., Sheeba, P., Ajini, K., Sajeev, A., Smitha, K., Rahmathulla, L., Ramakrishna, T., and David, Smith

Subjects
Alzheimer's disease -- Risk factors -- Diagnosis -- Research, Medical screening -- Methods -- Analysis -- Usage -- Research, Health, Foreign language translation software, Diagnosis, Analysis, Usage, Research, Risk factors, Methods
Abstract

Byline: Celeste. de Jager, Madhav. Thambisetty, K. Praveen, P. Sheeba, K. Ajini, A. Sajeev, K. Smitha, L. Rahmathulla, T. Ramakrishna, Smith. David Background: Alzheimer's disease (AD) is suspected to be [...]

Published
2008

133. Evidence for brain glucose dysregulation in Alzheimer's disease

Author

An, Yang, primary, Varma, Vijay R., additional, Varma, Sudhir, additional, Casanova, Ramon, additional, Dammer, Eric, additional, Pletnikova, Olga, additional, Chia, Chee W., additional, Egan, Josephine M., additional, Ferrucci, Luigi, additional, Troncoso, Juan, additional, Levey, Allan I., additional, Lah, James, additional, Seyfried, Nicholas T., additional, Legido‐Quigley, Cristina, additional, O'Brien, Richard, additional, and Thambisetty, Madhav, additional

Published
2017
Full Text
View/download PDF

134. Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer’s Disease

Author

Kim, Min, primary, Nevado-Holgado, Alejo, additional, Whiley, Luke, additional, Snowden, Stuart G., additional, Soininen, Hilkka, additional, Kloszewska, Iwona, additional, Mecocci, Patrizia, additional, Tsolaki, Magda, additional, Vellas, Bruno, additional, Thambisetty, Madhav, additional, Dobson, Richard J.B., additional, Powell, John F., additional, Lupton, Michelle K., additional, Simmons, Andy, additional, Velayudhan, Latha, additional, Lovestone, Simon, additional, Proitsi, Petroula, additional, and Legido-Quigley, Cristina, additional

Published
2017
Full Text
View/download PDF

141. [IC‐P‐188]: ON EVALUATION OF TAU ACCUMULATIONS IN LONGITUDINAL STUDIES OF ALZHEIMER's DISEASE (AD): IMPLICATIONS FROM A PET STUDY WITH [18F]RO6958948

Author

Kuwabara, Hiroto, primary, Borroni, Edilio, additional, Comley, Robert A., additional, Roberts, Joshua, additional, Kitzmiller, Kelly, additional, Rosenberg, Paul B., additional, Thambisetty, Madhav, additional, Honer, Michael, additional, Klein, Gregory, additional, Gapasin, Lorena, additional, Gobbi, Luca, additional, and Wong, Dean F., additional

Published
2017
Full Text
View/download PDF

142. [P3-207]: THE ENDOPHENOTYPE ASSOCIATION SCORE IN EARLY ALZHEIMER's DISEASE (EASE-AD): DISCOVERING NOVEL BLOOD AND BRAIN METABOLITE SIGNATURES OF PATHOLOGY AND PROGRESSION

Author

Varma, Vijay R., primary, Oommenn, Anup, additional, Varma, Sudhir, additional, Casanova, Ramon, additional, An, Yang, additional, Andrews, Ryan, additional, O'Brien, Richard, additional, Pletnikova, Olga, additional, Troncoso, Juan C., additional, Legido-Quigley, Cristina, additional, and Thambisetty, Madhav, additional

Published
2017
Full Text
View/download PDF

143. Metabolic network failures in Alzheimer's disease: A biochemical road map

Author

Toledo, Jon B., primary, Arnold, Matthias, additional, Kastenmüller, Gabi, additional, Chang, Rui, additional, Baillie, Rebecca A., additional, Han, Xianlin, additional, Thambisetty, Madhav, additional, Tenenbaum, Jessica D., additional, Suhre, Karsten, additional, Thompson, J. Will, additional, John‐Williams, Lisa St., additional, MahmoudianDehkordi, Siamak, additional, Rotroff, Daniel M., additional, Jack, John R., additional, Motsinger‐Reif, Alison, additional, Risacher, Shannon L., additional, Blach, Colette, additional, Lucas, Joseph E., additional, Massaro, Tyler, additional, Louie, Gregory, additional, Zhu, Hongjie, additional, Dallmann, Guido, additional, Klavins, Kristaps, additional, Koal, Therese, additional, Kim, Sungeun, additional, Nho, Kwangsik, additional, Shen, Li, additional, Casanova, Ramon, additional, Varma, Sudhir, additional, Legido‐Quigley, Cristina, additional, Moseley, M. Arthur, additional, Zhu, Kuixi, additional, Henrion, Marc Y.R., additional, van der Lee, Sven J., additional, Harms, Amy C., additional, Demirkan, Ayse, additional, Hankemeier, Thomas, additional, van Duijn, Cornelia M., additional, Trojanowski, John Q., additional, Shaw, Leslie M., additional, Saykin, Andrew J., additional, Weiner, Michael W., additional, Doraiswamy, P. Murali, additional, and Kaddurah‐Daouk, Rima, additional

Published
2017
Full Text
View/download PDF

146. A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease

Author

Seyfried, Nicholas T., primary, Dammer, Eric B., additional, Swarup, Vivek, additional, Nandakumar, Divya, additional, Duong, Duc M., additional, Yin, Luming, additional, Deng, Qiudong, additional, Nguyen, Tram, additional, Hales, Chadwick M., additional, Wingo, Thomas, additional, Glass, Jonathan, additional, Gearing, Marla, additional, Thambisetty, Madhav, additional, Troncoso, Juan C., additional, Geschwind, Daniel H., additional, Lah, James J., additional, and Levey, Allan I., additional

Published
2017
Full Text
View/download PDF

148. Lecanemab trial in AD brings hope but requires greater clarity.

Author

Thambisetty, Madhav and Howard, Robert

Subjects
*CEREBRAL amyloid angiopathy, *ALZHEIMER'S disease, *HOPE, *CLINICAL trials, *LECANEMAB
Abstract

The phase III Clarity AD clinical trial of lecanemab, an amyloid-targeting antibody, showed a small clinical benefit in people with Alzheimer disease. However, several questions remain regarding the true clinical relevance, safety and accessibility of lecanemab in this patient population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

150. Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain

Author

Wingo, Aliza P., Fan, Wen, Duong, Duc M., Gerasimov, Ekaterina S., Dammer, Eric B., Liu, Yue, Harerimana, Nadia V., White, Bartholomew, Thambisetty, Madhav, Troncoso, Juan C., Kim, Namhee, Schneider, Julie A., Hajjar, Ihab M., Lah, James J., Bennett, David A., Seyfried, Nicholas T., Levey, Allan I., and Wingo, Thomas S.

Abstract

Cerebral atherosclerosis contributes to dementia via unclear processes. We performed proteomic sequencing of dorsolateral prefrontal cortex in 438 older individuals and found associations between cerebral atherosclerosis and reduced synaptic signaling and RNA splicing and increased oligodendrocyte development and myelination. Consistently, single-cell RNA sequencing showed cerebral atherosclerosis associated with higher oligodendrocyte abundance. A subset of proteins and modules associated with cerebral atherosclerosis was also associated with Alzheimer’s disease, suggesting shared mechanisms.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results